Drug intelligence / Profile preview

Xiaoer Chiqiao Qingre

Development stage: Unknown
Lead developer: Jichuan Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

Xiaoer Chiqiao Qingre is a Traditional Chinese Medicine (TCM) granule formulation developed and manufactured by Jichuan Pharmaceutical Group. It is primarily indicated for the treatment of pediatric wind-heat common cold, characterized by symptoms such as fever, cough, sore throat, nasal congestion, and thirst. The formula is designed to clear heat, detoxify, and disperse wind-heat. It is a complex mixture of several herbal ingredients, including Forsythiae Fructus, Sojae Semen Praeparatum, and Scutellariae Radix. It is one of the most widely prescribed pediatric TCM cold medicines in China, often used to manage upper respiratory tract infections in children.

Brand names: TongnuoXiaoer Chiqiao Qingre Keli
Other names: Xiaoer Chiqiao Qingre Granules小儿豉翘清热颗粒

Beyond the preview

Go deeper on Xiaoer Chiqiao Qingre.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiaoer Chiqiao Qingre.

Explore the full profile